and today everyone is an "expert" on the subject. Second, physicians were asked to be more aggressive in treating patients with hypercholesterolemia.
In an unprecedented and innovative move, the LSP set performance standards for bias (accuracy) and reproducibility (precision) that all laboratories were expected to meet or -exceed (3). Appropriately, initial laboratory performance standards were set at a realistic level of a 5% allowable bias and a CV of 5%; a 5-year period was allowed for laboratories to achieve the final objective of 3% for both bias and CV. The laboratory communitycomposed of laboratory, industry, government, and other workers-united to work toward the final goal. At the same time, numerous articles appeared in newspapers and magazines to highlight problems associated with cholesterol measurement inaccuracies, especially between laboratories.
The public outcry was heard and probably had a significant role in legislative initiatives passed by Congress in the Clinical Laboratory Improvement Amendments (CLIA) in 1988 (4).
Over the past several years laboratories have been criticized for their inabifity to perform accurate and precise cholesterol analyses. However, laboratories today are capable of performing cholesterol analyses with the accuracy and precision to meet medical needs. A review of the past 20 years of cholesterol initiatives provides some insight about how a system evolved to achieve medical needs. Evolution of the total cholesterol system has been an iterative process that provides a model that should be used for other critical analytes (Figure 1 ). In addition, we discuss the within-individual 
meth-
ods to ensure achievement of analytical requirements within the medical need.
EvolutIon of Cholesterol Measurements
Here, we review briefly the significant activities that influenced the evolution of cholesterol procedures used throughout clinical laboratories today. In 1952 a "simplified" method for cholesterol analysis was reported (5), and today the Abell-Kendall method is the basis of the Reference Method for cholesterol. By current laboratory standards, the Abell-Kendall procedure is far from a "simplified" approach, yet this method plays a prominent role in the cholesterol standardization effort. The 20-year timeline in Figure 2 represents In addition, the goal for all laboratories to achieve comparable cholesterol measurements is identical to the primary objective of LRC laboratories.
"All laboratories" may refer to the 15 000-20 000 large hospital laboratories or possibly even 250 000 laboratories if clinics and doctors' offices are included. In either case, the task is formidable. Therefore, much has been and may be learned from the experiences of LRC laboratories to meet today's needs.
Transition to Enzyme Assays
Laboratories select analytical methods on the basis of a variety of criteria.
Fraser The influence of CDC on the LRC program cannot be overemphasized.
The laboratory success of the study can be traced to the insistence from CDC that NIH not allow the study to begin before all these laboratories were standardized.
That laboratory needs should sway or dictate the start of a study of this magnitude is a rare occurrence.
Although LRC laboratories are no longer active as such, they continue to have a strong influence on several current activities in lipid and lipoprotein programs. LRC laboratories form the backbone of the NRSC Network Laboratories (Table 1) and number of specimens required to achieve the goal of CV1 <5%. The last column was added to highlight the CV1 obtainable if the "perfect" analytical system (no imprecision nor bias) is used. Two messages become obvious from the relationship of CVA and CVB to CV1. First, an analytical assay that exhibits high variability, such as 5%, requires replicate analysis to improve the significance of the measurement. Most important, even with a "perfect" assay, multiple specimens must be collected to account for the CVB of 6.5% and reduce CV1 to <5%. Therefore, before a physician can confidently assess an individual's "true" cholesterol value, multiple specimens must be collected from that individual and assayed.
What does CVB = 6.5% represent in terms of confidence interval? For an individual with a "true" cholesterol of 5.20 mmolfL (200 mg/dL) and a CVB of 6.5%, and an error-free analytical procedure, the expected range of because the analyte cannot be defined; it is a mixture of several substances. Jack Levine: One of the ways that we in the industry have been able to remove bias from the calculation of error is that the lipid Laboratory Network is available to everybody. We, as manufacturers, can use it to get our methods certified. Our customers can also get certifled by a similar type of study. This is a big plus for all of us trying to get to a better answer; it removes the major bias components from our calculations. It has really helped us in the industry, and it helps the individual users to make sure they are on track and to check on their suppliers.
Your concerns about biological variation and laboratory variation and explaining this to physicians and the general public will add a new dimension to their understanding of laboratory data. When we tell the public there is a ± 30 or 40 mg/dL variation at a cholesterol concentration of 200 mg/dL, they are not going to be able to accept that cognitively.
We simply have to say the result is 200 and that's it. We can't start telling the public there is this plus or minus level of uncertainty. They can't deal with it; they can't be educated to deal with uncertainty. 
